Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISHL HL Update 2021 | Personalized approaches to Hodgkin lymphoma

Alison Moskowitz • 19 Mar 2021
ISHL HL Update 2021
Hodgkin Lymphoma Lymphoma

Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, touches on the importance of a personalized treatment approach in the management of Hodgkin lymphoma, as well as the identification of novel response biomarkers that can guide treatment strategies in this patient population. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.

More from Alison Moskowitz

2:50
Less aggressive approaches in relapsed/refractory Hodgkin lymphoma
Alison Moskowitz • 19 Mar 2021
5:01
Relapsed & refractory classic Hodgkin lymphoma
Alison Moskowitz • 19 Mar 2021
2:36
Angioimmunoblastic T-cell lymphoma treatment
Alison Moskowitz • 2 Jun 2019
1:17
Changes in second-line lymphoma treatment
Alison Moskowitz • 2 Jun 2019

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals